Milestone Pharma FY2025 net loss $63.1M; CARDAMYST launch on track; cash runway into late 2027

Milestone Pharmaceuticals Inc.

Net loss of $63.1M ($0.75 per share) for FY2025 vs $41.5M ($0.67) prior year.
Revenue of $1.5M from CARDAMYST FDA approval milestone under Corxel agreement.
Commercial expense $28.3M for FY2025; 60-person sales force deployed mid-Feb.
Pro forma cash $200M including $75M RTW payment and $19M ATM/warrant exercises; runway to late 2027.
EMA accepted MAA for etripamil; decision expected H1 2027.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.8

Milestone Pharmaceuticals Inc. reported financial results for the fourth quarter and fiscal year ended December 31, 2025.

Period: the fourth quarter and fiscal year ended December 31, 2025
Result: reported results

Exact text from the filing

On March 20, 2026, Milestone Pharmaceuticals Inc. issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2025

View on SEC.gov

22 earnings releases filed in the last 30 days. Browse all earnings releases →

Milestone Pharmaceuticals Inc. filing history →

Source: SEC EDGAR

accession 0001104659-26-032427

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.